Jade Biosciences, Inc.

NasdaqCM:JBIO Stock Report

Market Cap: US$1.3b

Jade Biosciences Management

Management criteria checks 0/4

Jade Biosciences' CEO is Tom Frohlich, appointed in Oct 2024, has a tenure of 1.75 years. total yearly compensation is $9.80M, comprised of 6.3% salary and 93.7% bonuses, including company stock and options. directly owns 0.013% of the company’s shares, worth $163.05K. The average tenure of the management team and the board of directors is 1 years and 1.8 years respectively.

Key information

Tom Frohlich

Chief executive officer

US$9.8m

Total compensation

CEO salary percentage6.35%
CEO tenure1.8yrs
CEO ownership0.01%
Management average tenure1yr
Board average tenure1.8yrs

Recent management updates

Recent updates

Analysis Article • Apr 21

We're Hopeful That Jade Biosciences (NASDAQ:JBIO) Will Use Its Cash Wisely

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Seeking Alpha • Apr 19

Jade Biosciences: Caution Advised Before Clinical Trial Results

Summary Jade Biosciences is a pre-revenue biotech focused on JADE101 for IgA nephropathy, offering potential high potency and dosing advantages. I rate JBIO a Hold due to binary risk: success could increase the share price, but failure in key trials could cause severe downside or bankruptcy. JADE101's femtomolar affinity offers 750x potency over competitors, but JBIO is years behind rivals like Otsuka’s Voyxact, facing significant execution and market risks. JBIO’s $88M cash and $247.7M short-term investments provide runway to 2028, but further equity raises are likely before expected revenue in 2029. Read the full article on Seeking Alpha

CEO Compensation Analysis

How has Tom Frohlich's remuneration changed compared to Jade Biosciences's earnings?
DateTotal CompensationSalaryCompany Earnings
Mar 31 2026n/an/a

-US$95m

Dec 31 2025US$10mUS$622k

-US$100m

Dec 31 2024US$2mUS$147k

-US$94m

Compensation vs Market: Tom's total compensation ($USD9.80M) is above average for companies of similar size in the US market ($USD5.14M).

Compensation vs Earnings: Tom's compensation has increased whilst the company is unprofitable.

CEO

Tom Frohlich (50 yo)

1.8yrs
Tenure
US$9,799,759
Compensation

Mr. Tom Frohlich is President, Chief Executive Officer & Director of Jade Biosciences, Inc. since October 2024. Mr. Frohlich serves as Independent Director of Nested Therapeutics since February 2024. He se...

Leadership Team

NamePositionTenureCompensationOwnership
Tom Frohlich
President1.8yrsUS$9.80m0.013%
$ 163.1k
Bradford Dahms
CFO & Treasurer1yrUS$4.13mno data
Andrew King
President of Research & Developmentless than a yearUS$4.54m0.23%
$ 2.9m
Elizabeth Balta
Chief Legal Officer & Corporate Secretary1.8yrsno datano data
Lori Stewart
Senior Vice President of Peopleno datano datano data
Jonathan Quick
Senior Vice President of Financeno datano datano data
Valerie Fauvelle
Senior Vice President of Regulatory & Qualityno datano datano data
Amy Sullivan
Senior Vice President of Development Operationsno datano datano data
Sandy Lewis
Senior Vice Presidentno datano datano data
Edward Conner
Chief Medical Officerless than a yearno datano data
1.0yrs
Average Tenure
50yo
Average Age

Experienced Management: JBIO's management team is not considered experienced ( 1 years average tenure), which suggests a new team.

Board Members

NamePositionTenureCompensationOwnership
Tom Frohlich
President1.8yrsUS$9.80m0.013%
$ 163.1k
Eric Dobmeier
Independent Chairman1.8yrsUS$226.94k0%
$ 0
Tomas Kiselak
Independent Director2yrsUS$206.35k0%
$ 0
Christopher Cain
Independent Director2yrsUS$205.67k0%
$ 0
Erin Lavelle
Independent Director1.8yrsUS$212.42k0%
$ 0
Lawrence Klein
Independent Director2yrsUS$210.06k0.057%
$ 734.1k
Mark Eisner
Directorless than a yearno datano data
1.8yrs
Average Tenure
49yo
Average Age

Experienced Board: JBIO's board of directors are not considered experienced ( 1.8 years average tenure), which suggests a new board.

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/07/06 07:55
End of Day Share Price 2026/07/02 00:00
Earnings2026/03/31
Annual Earnings2025/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Jade Biosciences, Inc. is covered by 9 analysts. 8 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Julian HarrisonBTIG
Vamil DivanGuggenheim Securities, LLC
Yu HeH.C. Wainwright & Co.